USA - engelsk - NLM (National Library of Medicine)

nanjing chemlin biomedical science & technology co, ltd. - crizotinib (unii: 53ah36668s) (crizotinib - unii:53ah36668s) -

Kenya - engelsk - Pharmacy and Poisons Board

crizotinib - capsule - crizotinib inn equavalent to 250mg crizotinib - crizotinib

Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - crizotinib - capsules, hard - 200

Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - crizotinib - capsules, hard - 250

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 200mg;  ;   - capsule - 200 mg - active: crizotinib 200mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 250mg;  ;   - capsule - 250 mg - active: crizotinib 250mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Den europeiske union - engelsk - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoma, non-small-cell lung - antineoplastic agents - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to

Canada - engelsk - Health Canada

pfizer canada ulc - crizotinib - capsule - 200mg - crizotinib 200mg - antineoplastic agents

Canada - engelsk - Health Canada

pfizer canada ulc - crizotinib - capsule - 250mg - crizotinib 250mg - antineoplastic agents

Den europeiske union - engelsk - myHealthbox

pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)